Document Type
Article
Peer Reviewed
1
Publication Date
4-14-2017
NLM Title Abbreviation
JAAD Case Rep
Journal/Book/Conference Title
JAAD Case Reports
PubMed ID
28459097
DOI of Published Version
10.1016/j.jdcr.2017.01.027
Start Page
178
End Page
179
Total Pages
2
Abstract
Ibrutinib, an inhibitor of Bruton tyrosine kinase, is used in the treatment of lymphoid leukemias. Ibrutinib-induced panniculitis has been described as a rare cutaneous side effect. We describe a case of a septolobular, mixed inflammatory panniculitis with small-vessel vasculitis secondary to ibrutinib therapy.
Keywords
OAfund, ibrutinib, panniculitis, tuberculosis
Journal Article Version
Version of Record
Published Article/Book Citation
JAAD Case Reports 3(3) May 2017, Pages 178-179. https://doi.org/10.1016/j.jdcr.2017.01.027
Rights
Copyright (c) 2017 by the American Academy of Dermatology, Inc.
Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License.
URL
https://ir.uiowa.edu/dermatology_pubs/6